China obesity biotech gets $72M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 2 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by The $50K-a-day prob­lem in clin­i­cal tri­al en­roll­ment

SPOTLIGHT In Focus Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

news UniQure says FDA prefers randomized trial for Huntington's treatment Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima Phase 3 China obesity biotech gets $72M, including support from OrbiMed Ascendis wins FDA approval for achondroplasia drug, waits on EU action Novartis' Rhapsido shows promise in Phase 2 food allergy data

Mar 03 12:00 pm ET Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

Register to see thought-leaders across pharma and biotech present innovation strategies for drug development and new partnership and licensing opportunities to advance these concepts. sponsored by American Association for Cancer Research

endpoints pharma US International Trade Commission to take a closer look at Chinese biotech CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives Novartis, Takeda agree to enter third round of Medicare drug price negotiations Merck cuts more than 150 jobs at new North Carolina vaccine plant as Gardasil slumps

in case you missed it 1. Generate raises $400M IPO as CEO says era of AI-designed drugs is coming soon 2. Peer Review Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi exec 3. Padcev-Keytruda combo delivers more positive data in bladder cancer 4. WuXi XDC makes an ADC linker deal with Earendil for up to $885M 5. As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M 6.